Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia

Blood

Volumn 101, Issue 3, 2003, Pages 1087-1093

  Lanham, Stuart ^a,b,c   Hamblin, Terry ^a,b,c   Oscier, David ^a,b,c   Ibbotson, Rachel ^a,b,c   Stevenson, Freda ^a,b,c   Packham, Graham ^a,b,c  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD38 ANTIGEN; CD79A ANTIGEN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; META TYROSINE; PROTEIN; PROTEIN SYK KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPHENOTYPING; MALE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0037306842     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1822     Document Type: Article

References (27)

1. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol. 1999;17:399-408.
2. H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
3. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
4. Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 2001;98:2633-2639.
5. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98:181-186.
6. Hamblin TJ, Orchard JA, Gardiner A, Oscier DG, Davis Z, Stevenson FK. Immunoglobulin V genes and CD38 expression in CLL. Blood. 2000;95:2455-2456.
7. H gene mutational status and prognosis in chronic lymphocytic leukemia. Blood. 2001;97:1892-1893.
8. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023-1029.
9. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 2001;97:2777-2783.
10. Pets JO, Berthou C, Porakishvili N, et al. CD-5 induced apoptosis of B cells in some patients with chronic lymphocytic leukemia. Leukemia. 2002;16:44-52.
11. Lankester AC, van Schijndel GM, van der Schoot CE, van Oers MH, van Noesel CJ, van Lier RA. Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. Blood. 1995;86:1090-1097.
12. Semichon M, Merle-Beral H, Lang V, Bismuth G. Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells. Leukemia. 1997;11:1921-1928.
13. Zupo S, Isnardi L, Megna M, et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood. 1996;88:1365-1374.
14. Matsuuchi L, Gold MR. New views of BCR structure and organization. Curr Opin Immunol. 2001;13:270-277.
15. Healy JI, Goodnow CC. Positive versus negative signaling by lymphocyte antigen receptors. Annu Rev Immunol. 1998;16:645-670.
16. Zhang L, French RR, Chan HT, et al. The development of anti-CD79 monoclonal antibodies for treatment of B-cell neoplastic disease. Ther Immunol. 1995;2:191-202.
17. Yellen-Shaw A, Monroe JG. Differential responsiveness of immature- and mature-stage murine B cells to anti-IgM reflects both FcR-dependent and -independent mechanisms. Cell Immunol. 1992;145:339-350.
18. Zhang J, Billingsley ML, Kincaid RL, Siraganian RP. Phosphorylation of Syk activation loop tyrosines is essential for Syk function: an in vivo study using a specific anti-Syk activation loop phosphotyrosine antibody. J Biol Chem. 2000;275:35442-35447.
19. Zupo S, Massara R, Dono M, et al. Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood. 2000;95:1199-1206.
20. D'Arena G, Cascavilla N, Musto P, Bisogno RC, Pistolese G, Carotenuto M. CD79b expression in B-cell chronic lymphocytic leukemia. Haematologica. 2000;85:556-557.
21. Thompson AA, Talley JA, Do HN, et al. Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukaemia. Blood. 1997;90:1387-1394.
22. Alfarano A, Indraccolo S, Circosta P, et al. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukaemia. Blood. 1999;93:2327-2335.
23. Vilen BJ, Nakamura T, Cambier JC. Antigen-stimulated dissociation of BCR mlg from Ig-α/Ig-β: implications for receptor desensitization. Immunity. 1999;10:239-248.
24. Kim KM, Reth M. The B cell antigen receptor of class IgD induces a stronger and more prolonged protein tyrosine phosphoryfation than that of class IgM. J Exp Med. 1995;181:1005-1014.
25. Chapman CJ, Spellerberg MB, Hamblin TJ, Stevenson FK. Pattern of usage of the VH4-21 gene by B lymphocytes in a patient with EBV infection indicates ongoing mutation and class switching. Mol Immunol. 1995;32:347-353.
26. Bhat NM, Bieber MM, Spellerberg MB, Stevenson FK, Teng NN. Recognition of auto- and exoantigens by V4-34 gene encoded antibodies. Scand J Immunol. 2000;51:134-140.
27. Thorpe SJ, Boult CE, Stevenson FK, et al. Cold agglutinin activity is common among human monoclonal IgM Rh system antibodies using the V4-34 heavy chain variable gene segment. Transfusion. 1997;37:1111-1116.